Flexion Therapeutics, Inc. (FLXN): Price and Financial Metrics

Flexion Therapeutics, Inc. (FLXN)

Today's Latest Price: $12.15 USD

0.36 (3.05%)

Updated Oct 22 4:00pm

Add FLXN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

FLXN Stock Summary

  • Flexion Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 91.18% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -19.26 for Flexion Therapeutics Inc; that's greater than it is for merely 1.2% of US stocks.
  • Revenue growth over the past 12 months for Flexion Therapeutics Inc comes in at 83.92%, a number that bests 93.81% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to FLXN, based on their financial statements, market capitalization, and price volatility, are SONO, HLIT, GPRO, CYRN, and FIT.
  • FLXN's SEC filings can be seen here. And to visit Flexion Therapeutics Inc's official web site, go to www.flexiontherapeutics.com.

FLXN Stock Price Chart Interactive Chart >

Price chart for FLXN

FLXN Price/Volume Stats

Current price $12.15 52-week high $22.98
Prev. close $11.79 52-week low $5.01
Day low $11.87 Volume 254,400
Day high $12.24 Avg. volume 748,084
50-day MA $11.73 Dividend yield N/A
200-day MA $12.29 Market Cap 599.03M

Flexion Therapeutics, Inc. (FLXN) Company Bio

Flexion Therapeutics focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company was founded in 2007 and is based in Burlington, Massachusetts.

FLXN Latest News Stream

Event/Time News Detail
Loading, please wait...

FLXN Latest Social Stream

Loading social stream, please wait...

View Full FLXN Social Stream

Latest FLXN News From Around the Web

Below are the latest news stories about Flexion Therapeutics Inc that investors may wish to consider to help them evaluate FLXN as an investment opportunity.

Ampio Pharmaceuticals Is Waking Up From Its COVID-19 Slumber, Approaching Potential Approval For Severe OAK

Ampio Pharmaceuticals Inc. (AMPE) has had a long road to FDA approval for its osteoarthritis drug called Ampion. It's been 9 years and 5 clinical trials in the making, and they are in their final push for approval. There is clear evidence suggestive of approval for Ampion in osteoarthritis of...

Vision and Value on Seeking Alpha | September 16, 2020

Flexion Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference

BURLINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and…

GlobeNewswire | September 3, 2020

Flexion Therapeutics EPS misses by $0.07, misses on revenue

Flexion Therapeutics (FLXN): Q2 GAAP EPS of -$0.76 misses by $0.07.Revenue of $15.45M (-8.8% Y/Y) misses by $1.09M.Press Release...

Seeking Alpha | August 5, 2020

Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020

BURLINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2020…

GlobeNewswire | July 30, 2020

OK Boomer, Flexion Stock Is Made For You

Flexion Therapeutics (NASDAQ:FLXN) may be one of the best-kept secrets in biotech. The company has a product that addresses a condition that affects a growing number of Americans. But FLXN stock started tumbling at the beginning of the year.Source: Shutterstock And despite positive news about its flagship drug, Zilretta, it's struggling to reclaim its gains.There's a reason for that. The economy can't fully heal without a vaccine for the novel coronavirus or effective antiviral treatments. We both know it, and investors are investing in biotech accordingly.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Cybersecurity Stocks We Need Now More Than EverFortunately, it seems that the field is narrowing when it comes to viable vaccine candidates. And that mea...

Yahoo | July 24, 2020

Read More 'FLXN' Stories Here

FLXN Price Returns

1-mo 15.49%
3-mo -1.94%
6-mo 26.43%
1-year -21.61%
3-year -43.85%
5-year -21.66%
YTD -41.30%
2019 82.86%
2018 -54.79%
2017 31.65%
2016 -1.30%
2015 -4.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7473 seconds.